Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 721 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dementia Mild Clear all
Completed No phase listed Observational

Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)

NCT05364307
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Prescreener database
Other
Lead sponsor
Global Alzheimer's Platform Foundation
Other
Eligibility
50 Years to 90 Years
Enrollment
1,555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
San Diego, California • Santa Ana, California • Aventura, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 7, 2026, 9:33 PM EDT
Completed Phase 2 Interventional Results available

Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients

NCT04388254
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Simufilam 100 mg oral tablet, Placebo
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
Gilbert, Arizona • Surprise, Arizona • Imperial, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 7, 2026, 9:33 PM EDT
Completed No phase listed Observational

Quality Improvement PrecivityAD Clinician Survey (QUIP I)

NCT05477056
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline
Interventions
PrecivityAD blood test
Other
Lead sponsor
C2N Diagnostics
Industry
Eligibility
60 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 7, 2026, 9:33 PM EDT
Completed Phase 3 Interventional Results available

Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease

NCT01028053
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Flutemetamol (18F) Injection
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
60 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Oct 7, 2026, 9:33 PM EDT
Completed Not applicable Interventional

Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure

NCT05584241
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Amnestic Mild Cognitive Disorder
Interventions
Diagnostic Disclosure Protocol, Biomarker Disclosure Protocol
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 7, 2026, 9:33 PM EDT
Completed Phase 3 Interventional

Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment

NCT05894954
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia, Mild
Interventions
Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care, Lifestyle including diet, exercise, stress management
Dietary Supplement · Combination Product · Behavioral
Lead sponsor
Alzheimer's Prevention and Reversal Project, Inc.
Other
Eligibility
45 Years to 76 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Folsom, California • San Rafael, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 7, 2026, 9:33 PM EDT
Completed Phase 2Phase 3 Interventional

Enhanced CBTi for Older Adult Sleep and Cognition

NCT05015803
View directory record Official record
Conditions
Insomnia, Alzheimers Disease Related Dementias
Interventions
CBTi with Application, CBTi, Sleep Hygiene Education
Combination Product · Behavioral
Lead sponsor
Penn State University
Other
Eligibility
60 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 7, 2026, 9:33 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease

NCT03520998
View directory record Official record
Conditions
Alzheimer Disease, Mild to Moderate Alzheimer Disease
Interventions
GRF6019
Drug
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
60 Years to 90 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Lemon Grove, California • Long Beach, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 7, 2026, 9:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Strengthening Exercise on the Brain for Early Dementia and Normative Older Adults

NCT01264614
View directory record Official record
Conditions
Cognitive Decline, Dementia, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Strengthening exercise
Behavioral
Lead sponsor
Union College, New York
Other
Eligibility
55 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 7, 2026, 9:33 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The MObile AssessMENT of Behavioral and Psychological Symptoms of Dementia in Amnestic MCI and AD (MOMENT) Study

NCT04482036
View directory record Official record
Conditions
Alzheimer Disease, Mild Memory Disturbance, Mild Cognitive Impairment
Interventions
Mobile Phone Application Assessments, Standard Assessments
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 7, 2026, 9:33 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Study to Understand Novel Biomarkers in Researching Dementia

NCT06547099
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions
Clinical tau PET, Clinical amyloid test, Research blood collection, Cognitive assessments
Diagnostic Test · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 7, 2026, 9:33 PM EDT
Active, not recruiting Not applicable Interventional

Assessing Feasibility of Prolonged Repetitive Near Infrared Light Stimulation in Early to Mid-Stage Dementia

NCT03750409
View directory record Official record
Conditions
Mild to Moderate Dementia
Interventions
Helmet
Device
Lead sponsor
Baylor Research Institute
Other
Eligibility
50 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Elkins Park, Pennsylvania • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 7, 2026, 9:33 PM EDT
Completed Phase 2 Interventional Results available

Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

NCT02423200
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
VX-745
Drug
Lead sponsor
EIP Pharma Inc
Industry
Eligibility
60 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 7, 2026, 9:33 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Evolution of Memory Related Activity

NCT00902499
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 90 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2010 · Synced Oct 7, 2026, 9:33 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01

NCT06247345
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ADEL-Y01 - healty participants, Placebo - Healthy Participants, ADEL-Y01 - MCI/AD, Placebo - MCI/AD
Drug
Lead sponsor
Alzheimer's Disease Expert Lab (ADEL), Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
6
States / cities
Anaheim, California • Lady Lake, Florida • Maitland, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 7, 2026, 9:33 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Predictors of Cognitive Decline in Normal Aging

NCT00094939
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2009 · Synced Oct 7, 2026, 9:33 PM EDT
Recruiting Early Phase 1 Interventional

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314
View directory record Official record
Conditions
Depressive Symptoms, Depression, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 7, 2026, 9:33 PM EDT
Active, not recruiting Not applicable Interventional

Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease

NCT05417555
View directory record Official record
Conditions
Mild Cognitive Impairment, Amnestic Mild Cognitive Disorder, Deep Brain Stimulation, Mild Alzheimer's Disease
Interventions
Low-Intensity Focused Ultrasound Pulsation (LIFUP)
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 7, 2026, 9:33 PM EDT
Active, not recruiting Not applicable Interventional

Cognitive Screening Made Easy for PCPs - R33 Phase

NCT06162026
View directory record Official record
Conditions
Cognitive Impairment, Dementia, Mild, Cognitive Decline
Interventions
RACS app
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
60 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 7, 2026, 9:33 PM EDT
Terminated Phase 3 Interventional Results available

Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers

NCT00550420
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone XR
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
51 Years to 91 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Palo Alto, California • Deerfield Beach, Florida • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 7, 2026, 9:33 PM EDT
Enrolling by invitation No phase listed Observational

Integrating eSAGE With EHR Data Using Machine Learning for the Early Detection and Monitoring of Cognitive Impairment in Individuals

NCT06017505
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Mild Cognitive Impairment, Worried Well
Interventions
electronic self administered gerocognitive examination (eSAGE)
Diagnostic Test
Lead sponsor
Douglas Scharre
Other
Eligibility
50 Years and older
Enrollment
1,486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 7, 2026, 9:33 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Reference Database & Longitudinal Registry of the Normal and Pathological Aging Brain

NCT02875496
View directory record Official record
Conditions
Early Onset Alzheimer Disease, Mild Cognitive Impairment, Depression, Aging
Interventions
Not listed
Lead sponsor
ElMindA Ltd
Industry
Eligibility
50 Years to 85 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
The Villages, Florida
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 7, 2026, 9:33 PM EDT
Recruiting Not applicable Interventional

Music Therapy for Patients With Alzheimer's Disease

NCT05151562
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Virtual Music Therapy
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 7, 2026, 9:33 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

NCT01689246
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
TRx0237 150 mg/day, TRx0237 250 mg/day, Placebo
Drug
Lead sponsor
TauRx Therapeutics Ltd
Industry
Eligibility
Up to 89 Years
Enrollment
891 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
26
States / cities
Phoenix, Arizona • Laguna Hills, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 7, 2026, 9:33 PM EDT